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Abstract
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive genetic disease
characterized by the lack of reaction to noxious stimuli and anhidrosis. It is caused by mutations in the NTRK1
gene, which encodes the high affinity tyrosine kinase receptor I for Neurotrophic Growth Factor (NGF).
Case Presentation: We present the case of a female patient diagnosed with CIPA at the age of 8 months. The
patient is currently 6 years old and her psychomotor development conforms to her age (RMN, SPECT and
psychological study are in the range of normality). PCR amplification of DNA, followed by direct sequencing, was
used to investigate the presence of NTRK1 gene mutations. Reverse transcriptase (RT)-PCR amplification of RNA,
followed by cloning and sequencing of isolated RT-PCR products was used to characterize the effect of the
mutations on NTRK1 mRNA splicing. The clinical diagnosis of CIPA was confirmed by the detection of two splice-
site mutations in NTRK1, revealing that the patient was a compound heterozygote at this gene. One of these
alterations, c.574+1G>A, is located at the splice donor site of intron 5. We also found a second mutation, c.2206-2
A>G, not previously reported in the literature, which is located at the splice acceptor site of intron 16. Each parent
was confirmed to be a carrier for one of the mutations by DNA sequencing analysis. It has been proposed that the
c.574+1G>A mutation would cause exon 5 skipping during NTRK1 mRNA splicing. We could confirm this prediction
and, more importantly, we provide evidence that the novel c.2206-2A>G mutation also disrupts normal NTRK1
splicing, leading to the use of an alternative splice acceptor site within exon 17. As a consequence, this mutation
would result in the production of a mutant NTRK1 protein with a seven aminoacid in-frame deletion in its tyrosine
kinase domain.
Conclusions: We present the first description of a CIPA-associated NTRK1 mutation causing a short interstitial
deletion in the tyrosine kinase domain of the receptor. The possible phenotypical implications of this mutation are
discussed.
Background
Congenital Insensitivity to Pain with Anhidrosis (CIPA;
OMIM #256800), also called Hereditary Sensory and
Autonomic Neuropathy IV (HSAN IV), is an autosomal
recessive disorder, part of a group of rare genetic neuro-
pathies that affect the peripheral nervous system. CIPA
manifests itself in the first months of life as recurrent
fever episodes and self-mutilating behaviour [1]. The
clinical phenotype of patients with CIPA is characterized
by insensitivity to noxious stimuli, anhidrosis (inability
to sweat) and mental retardation [1,2]. The insensitivity
to superficial and deep pain is due to the absence of Aδ
and C primary afferent fibbers [3], whereas the lack of
sympathetic postganglionic neurons results in the inabil-
ity to control sweating [4]. Although it has been recently
proposed that the lack of some neurons in the brain
could be responsible for the mental retardation, learning
deficits, and emotional liability commonly found in
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these patients [5], the neurological basis for such defects
remains to be fully elucidated.
CIPA is caused by mutations in the NTRK1 gene
(OMIM *191315), also known as TRKA [6]. The NTRK1
gene is located on chromosome 1 (1q21-q22), is divided
into 17 exons, and encodes the high affinity tyrosine
kinase receptor I for Neurotrophic Growth Factor
(NGF) [7], which is responsible for the correct differen-
tiation and survival of sympathetic ganglion and noci-
ceptive sensory neurons [8,9]. Several different NTRK1
gene alterations, including nucleotide substitutions,
insertions and deletions, have been identified in patients
with CIPA [6,10-19].
CIPA-related mutations have been detected in almost
every NTRK1 exon, as well as in several intervening
intronic sequences (IVS). Some of the exonic mutations
are nonsense and frameshift changes, which are likely to
produce a truncated, non-functional, NTRK1 protein, or
an aberrant mRNA that may be degraded by the non-
sense-mediated decay system [20]. In addition, most
missense mutations in NTRK1 exons have been shown,
using in vitro functional assays, to completely abrogate
receptor activity, although partial receptor inactivation
has also been reported for two changes in exons 14 and
15 [21-23]. IVS mutations, on the other hand, are com-
monly predicted to disrupt proper NTRK1 mRNA spli-
cing [6,10-13,15,19], but the necessary RNA analyses to
confirm this prediction have been carried out only in
some of the studies [6,10,11,14].
In this report, we describe the case of a Spanish
patient with CIPA showing a clinical phenotype charac-
terized by sensory loss affecting the perception of pain
and temperature, and by absence of sweating, but with-
out developmental delay. NTRK1 gene analysis revealed
the presence of two novel splice site mutations in IVS 5
and IVS 16, whose effect on NTRK1 mRNA splicing was
subsequently characterized in detail. On the basis of
mRNA analysis, one of mutations reported here is pre-
dicted to cause a seven amino acid in frame interstitial
deletion within the tyrosine kinase domain of the
NTRK1 protein. We discuss the potential functional
consequences of this novel NTRK1 mutation.
Case Presentation
Clinical data
We describe the case of a 6 year old female, who was
diagnosed with CIPA at the age of 8 months, when she
suffered of prolonged fever of unkown origin. Physical
examination did not reveal any dysmorphic traits. Initi-
ally, the only remarkable features were leukokeratosis in
the tongue and periungueal bitting injuries. The anato-
mopathological study of these injuries revealed an
epithelial hyperplasia with orthoparakeratosis. The diag-
nosis of CIPA was based on the negative results of the
histamine and pilocarpine testing, as well as on the nor-
mal electromyography results, with absence of sym-
pathic-cutaneous response. The results of the rest of
complementary analyses performed (karyotype, aminoa-
cids, humoral and cellular immunity, autoantibodies,
ophthalmic examination and brain NMR) were normal.
The patient displayed several of the features that char-
acterize the CIPA phenotype, including insensitivity to
pain, anhidrosis and defects in thermoregulation leading
to episodes of hyperpyrexia associated with high envir-
onmental temperature. She also presented feeding diffi-
culties, with poor food oral intake in the first years of
life. Her weight was on the third percentile. In addition,
she had eczematous lesions in skin folds, generalized
xerosis, pityriasis alba in upper limbs and hyperkeratosis
in palms and soles. However, neither hip dislocation nor
chronic osteomyelitis were observed, and her develop-
mental milestones (head lifting, crawling, sitting, stand-
ing, walking and talking) were not delayed.
Psychological evaluation and SPECT were normal at the
age of 6 years.
Written informed consent was obtained from the
patient and all the family members participating in this
study. This research work was approved by the Ethical
Committee of Basurto University Hospital, conforming
to Helsinki Declaration.
Identification and characterization of two novel NTRK1
intronic mutations
In addition to the patient, her parents and sister were
also available for molecular analysis. The pedigree of the
family is shown in Figure 1. Blood samples were col-
lected from all the family members. Genomic DNA was
purified using a standard “salting-out” purification pro-
tocol. Total RNA was obtained using the Puregene RNA
isolation kit (Gentra). The concentration of both DNA
and RNA was measured using a spectrophotometer. All
the 17 exons and intron-exon boundaries of the longest
NTRK1 isoform (NM_002529) were analysed using PCR
amplification of genomic DNA from the patient fol-
lowed by direct DNA sequencing. The presence of the
identified NTRK1 mutations was subsequently investi-
gated in her relatives using the same methods. Primers
for PCR amplification were designed using the Primer3
on-line application (http://frodo.wi.mit.edu/primer3/
input.htm). Primer sequences and optimal annealing
temperature for each primer pair are available upon
request. All PCR reactions were carried out using Taq-
Gold DNA polymerase (Applied Biosystems) with 5%
DMSO (Sigma). Direct sequencing of both strands of
the amplified DNA fragments was performed using the
BigDye Terminator v3.1 Sequencing kit (Applied Biosys-
tems). Sequencing reactions were analysed on an ABI
PRISM 3130 Genetic Analyzer using the Sequence
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Scanner software (Applied Biosystems). The mutations
described in this report are named following the recom-
mendations from the Human Genome Variation Society
(http://www.hgvs.org/mutnomen/).
One μg total RNA was reverse-transcribed using the
SuperScript VILO cDNA Synthesis kit (Invitrogen), to
generate complementary DNA (cDNA). Two sets of spe-
cific primers (P1-F/P1-R and P2-F/P2-R), whose location
is indicated in Figure 2, were designed as described
above. PCR reactions with each of the primer sets were
carried out using 2 μl of cDNA. PCR products were
inserted into the pCR2.1-TOPO vector using the TOPO
TA Cloning kit (Invitrogen). DNA was extracted from
20 randomly selected bacterial clones. The size of the
inserted PCR fragment in each clone was determined
using PCR with a set of primers directed against vector
sequences flanking the cloning site. Plasmid DNA from
bacterial clones containing inserted PCR products of dif-
ferent size was purified using the QIAprep Spin Mini-
prep Kit (Qiagen) and sequenced as described above.
Analysis of genomic DNA from the patient revealed
the presence of two intronic NTRK1 mutations in com-
pound heterozygosis (Figure 1B). The first mutation is a
G to C change disrupting the 5’ splice site of IVS 5
(c.574+1G>C). The second mutation is an A to G
change that disrupts the 3’splice site of IVS 16 (c.2206-
2A>G). Both the father and sister of the patient were
shown to be carriers for the c.2206-2A>G mutation,
whereas her mother was shown to be a carrier for the
c.574+1G>C mutation. To the best of our knowledge,
these splice-site mutations in NTRK1 gene have not
been previously described in patients with CIPA,
although a different change affecting the first nucleotide
of IVS 5 (c.574+1G>A) has been reported in an earlier
study [12].
To assess the consequences of the c.574+1G>C and
c.2206-2A>G mutations on NTRK1 splicing, we carried
out a detailed analysis on mRNA obtained from the
patient and her relatives. RNA was reverse-transcribed
into cDNA, and amplified by PCR using the primer sets
depicted in Figure 2A. We hypothesized that an altera-
tion of the normal splicing caused by the IVS mutations
would result in a mixture of differently sized amplified
products. To evaluate this possibility, PCR amplification
products obtained with primer sets P1-F/P1-R and P2-
F/P2-R were cloned into the pCR2.1-TOPO vector. In
each case, 20 bacterial clones were screened for the pre-
sence or inserts of difference size, using PCR with pri-
mers specific for vector sequences flanking the cloning
site.
As shown in Figure 2B, amplification of patient RNA
with P1-F/P1-R primer set produced two different PCR
fragments of 339 and 193 bp. Subsequently, DNA
sequencing showed that the 339 bp fragment
Figure 1 Pedigree of the family and results of the NTRK1 genetic analysis in CIPA patients’ DNA. A. As indicated by the symbols in the
pedigree, individual II-1 is affected by CIPA, whereas her parents and sister are all carriers. The NTRK1 mutation detected in each individual is
indicated under the corresponding symbol. B. Electropherograms demonstrating the presence of two NTRK1 point mutations (in IVS5 and IVS16)
in DNA from individual II-1. The position of each mutation is indicated by an asterisk.
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Figure 2 Characterization of the effect of IVS 5 (c.574+1G>C) and IVS16 (c.2206-2A>G) point mutations on NTRK1 splicing. A.
Schematic partial representation of NTRK1 exon/IVS structure, indicating the position of the primer sets (P1-F/P1-R and P2-F/P2-R) designed for
RT-PCR analysis. B. Left, agarose gel showing the two differently sized amplicons obtained by PCR analysis of cloned P1-F/P1-R RT-PCR products
(see “Methods” section for details). As illustrated on the right, lane 1 fragment corresponds to normally spliced mRNA, encoding the wild-type
(wt) NTRK1 protein, whose structural domains are schematically depicted in the figure (LRM: leucine-rich motif; IGL: immunoglobulin-like; TM:
transmembrane; TK: tyrosine kinase). Lane 2 fragment corresponds to an abnormally spliced mRNA lacking exon 5. The encoded NTRK1 protein,
depicted below, is predicted to bear a premature stop codon following a novel 64 aminoacid sequence after the L100 residue. C. Left, agarose
gel showing the three differently sized amplicons obtained by PCR analysis of cloned P2-F/P2-R RT-PCR products. Lane 1 corresponds to
normally spliced mRNA. Lane 2 corresponds to an abnormally spliced mRNA retaining a 336 bp fragment of IVS16. The predicted NTRK1 protein,
depicted below, would have a premature stop codon following a novel 5 aminoacid sequence after the E375 residue. Lane 3 corresponds to an
abnormally spliced mRNA lacking a 21 bp fragment of exon 17. As indicated, this in frame deletion is predicted to encode an NTRK1 protein
bearing a 7 aminoacid interstitial (A736_Q742del) deletion in its TK domain.
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corresponded to normally spliced mRNA, whereas the
193 bp fragment corresponded to an mRNA lacking
exon 5. This analysis, therefore, demonstrates that the
c.574+1G>C mutation causes exon 5 skipping. Skipping
of exon 5, in turn, results in a frame shift which, as illu-
strated in Figure 2B, is predicted to lead to a truncated
protein, bearing a novel premature stop codon following
a novel 64 amino acid sequence after L100 residue. On
the other hand, three products of 218, 239 and 573 bp
were obtained by RT-PCR amplification of patient RNA
with P2-F/P2-R primer set (Figure 2C). In addition to
the normally spliced mRNA, DNA sequencing revealed
the presence of two abnormally spliced mRNA variants,
one of them retaining 336 bp of IVS 16, and the second
one showing a deletion of the first 21 bp of exon 17.
Thus, the c.2206-2A>G mutation leads to the produc-
tion of two different abnormally spliced mRNA forms.
As schematically depicted in Figure 2C, partial retention
of IVS 16 is predicted to result in a truncated NTRK1
protein, bearing a premature stop codon following a
novel 5 amino acid sequence after the E735 residue.
The 21 bp, in frame deletion of exon 17, on the other
hand, would result in a 7 amino acid interstitial deletion
(A736_Q742del) in the tyrosine kinase (TK) domain of
NTRK1 protein. RT-PCR analysis on RNA from the
remaining family members produced consistent results
(not shown). Thus, exon 5 skipping was demonstrated
in the mother of the patient, who is a carrier for the
c.574+1G>C mutation, whereas the mRNA variants with
the partial IVS16 retention and the partial exon 17 dele-
tion were detected in the father and sister of the pro-
band, who are carriers for the c.2206-2A>G mutation.
We report here a case of compound heterozygosis for
two novel NTRK1 splice site mutations in a 6 year old
patient with autosomal recessive congenital insensitivity
to pain with anhidrosis (CIPA). Using RNA analysis, we
show that both mutations cause abnormal splicing of
NTRK1 mRNA. One of the mutations (c.574+1G>C)
disrupts the 5’ splice site of IVS 5. Of note, a different
mutation of the same nucleotide (c.574+1G>A) was pre-
viously detected in a patient with CIPA [12]. This muta-
tion was postulated to cause NTRK1 exon 5 skipping,
but no evidence for such an effect was provided. Here,
we show that the c.574+1G>C change does, in fact, lead
to skipping of exon 5. The second mutation identified in
our patient (c.2206-2A>G) disrupts the 3’splice site of
IVS 16, and results in the production of two different
abnormally spliced mRNA variants, one showing partial
retention of IVS16, and the other one showing partial
deletion of exon 17, which may be due, as previously
suggested, to the activation of cryptic splice sites [6]. In
summary, three different altered NTRK1 mRNAs can be
detected in the patient. Of note, NTRK1 splice site
mutations leading to the production of more than one
abnormal splicing product have been previously
described in CIPA patients [6,14]. The skipping of exon
5 caused by the c.574+1G>C mutation introduces a
frame shift that is predicted to result in a severely trun-
cated, non-functional NTRK1 protein (Figure 2B). The
c.2206-2A>G mutation is of greater interest in the con-
text of the present report due to its novelty. However,
predicting the functional consequences of this mutation
is not, in our opinion, straightforward. The aberrant
splicing product retaining part of IVS 16 would be
translated into a presumably non-functional, truncated
NTRK1 protein, lacking the carboxy-terminal part of its
TK domain (Figure 2C). However, the abnormal splicing
variant lacking the first 21 bp of exon 17 maintains the
correct reading frame, and would be translated into a
NTRK1 protein bearing a short in frame deletion of
seven aminoacids (A736_Q742del). Two longer intersti-
tial deletions in NTRK1 extracellular domain have been
previously described in a patient with CIPA homozygous
for the IVS 3 mutation c.359+G>T [14], but our study is
the first description of a CIPA-associated NTRK1 muta-
tion causing a short interstitial deletion in the tyrosine
kinase domain of the receptor.
We can only speculate about the consequences that
this short deletion may have on NTRK1 function. A
first possibility is that the deletion completely abrogates
NTRK1 signalling. It is also possible, however, that sig-
nalling through the mutant NRTK1 receptor is only par-
tially reduced. In this regard, partial NTRK1 inactivation
has been previously shown for two different CIPA-asso-
ciated exonic mutations [21-23]. We also have to take
into account that short TK domain deletions have been
shown to confer increased activity to other receptor tyr-
osine kinases (RTKs), such as the epidermal growth fac-
tor receptor [24]. Although the functional consequences
of gain of function mutations in other RTKs cannot be
directly extrapolated to NTRK1 [25], we cannot formally
rule out the possibility that the A736_Q742del mutation
may increase NTRK1 activity. Finally, it is also possible
that, besides its kinase activity, other functional proper-
ties of the NTRK1 receptor, such as its correct axonal
trafficking or its access to the endocytic pathway, can be
altered by the short in frame deletion described here.
Future functional studies will be needed to examine
these possibilities.
Although the patient described in this report clearly
shows the clinical characteristics of CIPA [2,26], the
absence of evident developmental delay is remarkable.
The level of mental retardation is known to vary among
different CIPA patients [5], and it is not known if cer-
tain NTRK1 mutations correlate with a more severe
mental retardation phenotype. Undoubtedly, an early
diagnosis and the control of secondary clinical problems,
significantly improve prognosis and quality of life of
Sarasola et al. BMC Medical Genetics 2011, 12:86
http://www.biomedcentral.com/1471-2350/12/86
Page 5 of 7
CIPA patients. Preventive measures, such as the control
of hyperthermia in high environmental temperature to
avoid febrile seizures, or the avoidance of repeated and
unnoticed trauma and self-mutilation, may prevent per-
manent disabilities, and minimize the extent of charac-
teristic degenerative or destructive artropathy.
It is not possible to establish to what extent the nor-
mal development of the CIPA patient described here is
related to the nature of the NTRK1 mutations identified,
to her early diagnosis, or to a combination of both
factors.
Conclusions
We present here the first description of a CIPA-asso-
ciated NTRK1 mutation causing a short interstitial dele-
tion in the tyrosine kinase domain of the receptor, and
discuss its potential consequences. Identification of the
full spectrum of CIPA-related NTRK1 genetic defects
may facilitate future genotype-phenotype correlation
studies in CIPA patients.
Acknowledgements and Funding
The authors sincerely thank the family for their participation in this study.
This investigation was supported by the Instituto de Salud Carlos III and the
Fundación Vasca de Innovación e Investigación Sanitarias (funds to ES).
Author details
1Department of Genetics, Basurto University Hospital (OSAKIDETZA/Servicio
Vasco de Salud), Bilbao, Spain. 2Departament of Genetics, Physical
Anthropology and Animal Physiology, University of the Basque Country
(UPV/EHU), Leioa, Spain. 3Department of Pediatrics, Basurto University
Hospital (OSAKIDETZA/Servicio Vasco de Salud), Bilbao, Spain.
Authors’ contributions
ES, MJGB and JAR participated in the design of the study, performed the
molecular genetic studies and wrote the manuscript. EG and JA carried out
the clinical diagnosis and management of the patient and helped to draft
the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 October 2010 Accepted: 27 June 2011
Published: 27 June 2011
References
1. Swanson AG: Congenital insensitivity to pain with anhydrosis. A unique
syndrome in two male siblings. Arch Neurol 1963, 8:299-306.
2. Axelrod FB, Chelimsky GG, Weese-Mayer DE: Pediatric autonomic
disorders. Pediatrics 2006, 118:309-321.
3. Nolano M, Crisci C, Santoro L, Barbieri F, Casale R, Kennedy WR,
Wendelschafer-Crabb G, Provitera V, Di Lorenzo N, Caruso G: Absent
innervation of skin and sweat glands in congenital insensitivity to pain
with anhidrosis. Clin Neurophysiol 2000, 111:1596-1601.
4. Verpoorten N, De Jonghe P, Timmerman V: Disease mechanisms in
hereditary sensory and autonomic neuropathies. Neurobiol Dis 2006,
21:247-255.
5. Indo Y: Nerve growth factor, interoception, and sympathetic neuron:
lesson from congenital insensitivity to pain with anhidrosis. Auton
Neurosci 2009, 147:3-8.
6. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H,
Tonoki H, Awaya Y, Matsuda I: Mutations in the TRKA/NGF receptor gene
in patients with congenital insensitivity to pain with anhidrosis. Nat
Genet 1996, 13:485-488.
7. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M: Molecular and
biochemical characterization of the human trk proto-oncogene. Mol Cell
Biol 1989, 9:24-33.
8. Levi-Montalcini R: The nerve growth factor 35 years later. Science 1987,
237:1154-1162.
9. Beigelman A, Levy J, Hadad N, Pinsk V, Haim A, Fruchtman Y, Levy R:
Abnormal neutrophil chemotactic activity in children with congenital
insensitivity to pain with anhidrosis (CIPA): the role of nerve growth
factor. Clin Immunol 2009, 130:365-372.
10. Mardy S, Miura Y, Endo F, Matsuda I, Sztriha L, Frossard P, Moosa A,
Ismail EA, Macaya A, Andria G, Toscano E, Gibson W, Graham GE, Indo Y:
Congenital insensitivity to pain with anhidrosis: novel mutations in the
TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth
factor. Am J Hum Genet 1999, 64:1570-1579.
11. Miura Y, Mardy S, Awaya Y, Nihei K, Endo F, Matsuda I, Indo Y: Mutation
and polymorphism analysis of the TRKA (NTRK1) gene encoding a high-
affinity receptor for nerve growth factor in congenital insensitivity to
pain with anhidrosis (CIPA) families. Hum Genet 2000, 106:116-124.
12. Bodzioch M, Lapicka K, Aslanidis C, Kacinski M, Schmitz G: Two novel
mutant alleles of the gene encoding neurotrophic tyrosine kinase
receptor type 1 (NTRK1) in a patient with congenital insensitivity to pain
with anhidrosis: a splice junction mutation in intron 5 and cluster of
four mutations in exon 15. Hum Mutat 2001, 17:72.
13. Indo Y, Mardy S, Miura Y, Moosa A, Ismail EA, Toscano E, Andria G,
Pavone V, Brown DL, Brooks A, Endo F, Matsuda I: Congenital insensitivity
to pain with anhidrosis (CIPA): novel mutations of the TRKA (NTRK1)
gene, a putative uniparental disomy, and a linkage of the mutant TRKA
and PKLR genes in a family with CIPA and pyruvate kinase deficiency.
Hum Mutat 2001, 18:308-318.
14. Bonkowsky JL, Johnson J, Carey JC, Smith AG, Swoboda KJ: An infant with
primary tooth loss and palmar hyperkeratosis: a novel mutation in the
NTRK1 gene causing congenital insensitivity to pain with anhidrosis.
Pediatrics 2003, 112:e237-241.
15. Verpoorten N, Claeys KG, Deprez L, Jacobs A, Van Gerwen V, Lagae L,
Arts WF, De Meirleir L, Keymolen K, Ceuterick-de Groote C, De Jonghe P,
Timmerman V, Nelis E: Novel frameshift and splice site mutations in the
neurotrophic tyrosine kinase receptor type 1 gene (NTRK1) associated
with hereditary sensory neuropathy type IV. Neuromuscul Disord 2006,
16:19-25.
16. Huehne K, Zweier C, Raab K, Odent S, Bonnaure-Mallet M, Sixou J,
Landrieu P, Goizet C, Sarlangue J, Baumann M, Eggermann T, Rauch A,
Ruppert S, Stettner GM, Rautenstrauss B: Novel missense, insertion and
deletion mutations in the neurotrophic tyrosine kinase receptor type 1
gene (NTRK1) associated with congenital insensitivity to pain with
anhidrosis. Neuromuscul Disord 2008, 18:159-166.
17. Tüysüz B, Bayrakli F, DiLuna ML, Bilguvar K, Bayri Y, Yalcinkaya C, Bursali A,
Ozdamar E, Korkmaz B, Mason CE, Ozturk AK, Lifton RP, State MW, Gunel M:
Novel NTRK1 mutations cause hereditary sensory and autonomic
neuropathy type IV: demonstration of a founder mutation in the Turkish
population. Neurogenetics 2008, 9:119-125.
18. Suriu C, Khayat M, Weiler M, Kfir N, Cohen C, Zinger A, Aslanidis C,
Schmitz G, Falik-Zaccai TC: Skoura - a genetic island for congenital
insensitivity to pain and anhidrosis among Moroccan Jews, as
determined by a novel mutation in the NTRK1 gene. Clin Genet 2009,
75:230-236.
19. Lee S, Lee J, Lee M, Kim J, Ki C: Clinical and genetic analysis of Korean
patients with congenital insensitivity to pain with anhidrosis. Muscle
Nerve 2009, 40:855-859.
20. Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N,
Mühlemann O: Nonsense-mediated mRNA decay in human cells:
mechanistic insights, functions beyond quality control and the double-
life of NMD factors. Cell Mol Life Sci 2010, 67:677-700.
21. Mardy S, Miura Y, Endo F, Matsuda I, Indo Y: Congenital insensitivity to
pain with anhidrosis (CIPA): effect of TRKA (NTRK1) missense mutations
on autophosphorylation of the receptor tyrosine kinase for nerve
growth factor. Hum Mol Genet 2001, 10:179-188.
22. Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA,
Greco A: Novel pathogenic mechanisms of congenital insensitivity to
pain with anhidrosis genetic disorder unveiled by functional analysis of
Sarasola et al. BMC Medical Genetics 2011, 12:86
http://www.biomedcentral.com/1471-2350/12/86
Page 6 of 7
neurotrophic tyrosine receptor kinase type 1/nerve growth factor
receptor mutations. J Biol Chem 2002, 277:6455-6462.
23. Miranda C, Selleri S, Pierotti MA, Greco A: The M581V mutation, associated
with a mild form of congenital insensitivity to pain with anhidrosis,
causes partial inactivation of the NTRK1 receptor. J Invest Dermatol 2002,
119:978-979.
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA,
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN,
Christiani DC, Settleman J, Haber DA: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
25. Miranda C, Zanotti G, Pagliardini S, Ponzetto C, Pierotti MA, Greco A: Gain
of function mutations of RTK conserved residues display differential
effects on NTRK1 kinase activity. Oncogene 2002, 21:8334-8339.
26. Freeman R: Autonomic peripheral neuropathy. Lancet 2005,
365:1259-1270.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/86/prepub
doi:10.1186/1471-2350-12-86
Cite this article as: Sarasola et al.: A short in-frame deletion in NTRK1
tyrosine kinase domain caused by a novel splice site mutation in a
patient with congenital insensitivity to pain with anhidrosis. BMC
Medical Genetics 2011 12:86.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sarasola et al. BMC Medical Genetics 2011, 12:86
http://www.biomedcentral.com/1471-2350/12/86
Page 7 of 7
